药物BCS分类系统.ppt_第1页
药物BCS分类系统.ppt_第2页
药物BCS分类系统.ppt_第3页
药物BCS分类系统.ppt_第4页
药物BCS分类系统.ppt_第5页
已阅读5页,还剩13页未读 继续免费阅读

下载本文档

版权说明:本文档由用户提供并上传,收益归属内容提供方,若内容存在侵权,请进行举报或认领

文档简介

PharmaceuticalDevelopmentwithFocusonPaediatricformulations WHO FIPTrainingWorkshopHyattRegencyHotelSaharAirportRoadAndheriEast Mumbai India28April2008 2May2008 BiopharmaceuticalClassificationSystem BCS Presentedby LembitR goMD PhDContactdetails DrLembitR goCoordinator QualityAssuranceandSafety MedicinesMedicinesPolicyandStandardsWorldHealthOrganizationGenevaSwitzerlandE Mail ragol who int BiopharmaceuticalClassificationSystem BCS BackgroundWhatisaproblem WhatisWHOdoingandplanningtodo Whatresourcesareavailable Conclusions Whatisthekeyformultisource generic pharmaceuticalproducts Newmedicines applicanthastoprovequality safetyandefficacyMultisource generic pharmaceuticalproducts applicanthastoprovequality incaseofsafetyandefficacyitreferstotheoriginatorproductThekeyisTHERAPEUTICINTERCHANGEABILITYItisassumedthatiftheconcentrationpatterninthebloodisessentiallythesamethenthesafetyandefficacyprofilemustbeessentiallythesame Therapeuticinterchangeability prerequisites ConstantandreproduciblequalityofMPPsManufacturedunderGMPCompliancewithallqualityspecificationsVariationscontrolNoconstantandreproduciblequality noneedforprovinginterchangeabilityasitismeaningless allbatchesdifferentanyhow Optionstoshowtherapeuticinterchangeabilityofmultisourcepharmaceuticalproducts MPP TheinvitroapproachreferstotheBiopharmaceuticsClassificationSystem BCS DrugsubstanceclassificationaccordingtotheBCS Activepharmaceuticalingredients APIs areclassifiedintoclassesbasedontheiraqueoussolubilityandpermeabilitycharacteristics InVitroApproaches Biowaiveroptions Thepossibilityof invitrodocumentationofbioequivalence for certainmedicinesanddosageforms isspecifiedinSection9oftheWHOguidancedocument 1 Ifthedrugsubstanceinquestionishighlysolubleandhighlypermeable BCSclassI andismanufacturedasanimmediatereleasedosageform exemptionfromaninvivopharmacokineticbioequivalencestudymaybeconsideredprovidedthatrelevantdissolutionrequirementsarefulfilled Principles Thesolubilityisnotmeanttobetheabsolutesolubilityhere Incontrasthighsolubilityreferstothehighestsingleunitdosetobecompletelysolublein250mlaqueousbuffermediumwithinthepHrangeof1 2to6 8withoutanystabilityproblems AsanotherrelatedphysicochemicalcharacteristichighpermeabilityshouldbedemonstratedfortheparticularAPIdemonstratingthatthefractiondoseabsorbedamountstoatleast85 Accordingly highpermeabilitywouldstandforalmostcompleteabsorptionofthecompoundinhumans PhysicochemicalmeasuresneededforBCSclassificationpurposesmaybetakenfromsoundliterature TheWHOModelListofEssentialMedicineshasbeenreviewedbasedontheBCSconceptandactivecompoundsareclassifiedaccordinglyintheappendixofrespectiveWHOdocument 1 Atheoreticalriskassessmentismandatorytominimizeriskforfalselywaivinganecessaryinvivostudy SituationswhereBCS basedbiowaiversarenotapplicable Assessmentofrisks practicalpoints Inpracticesomeofthecriterialistedinthetableforriskassessmentaredifficulttoassesse g themeaningof criticaluse or bioavailabilityproblems andareprobablynoteasytobedefined However publishedliteratureprovidesvaluableexamplesofhowtoevaluatetheapplicabilityoftheBCSbasedbiowaiverapproach seebiowaivermonographsonthefollowingslide Availableresources BiowaiverMonographs BiowaivermonographsareworkedoutbygroupofwellestablishedscientistslinkedtoFIPandpublishedinJournalofPharmaceuticalSciencesThesecanbeusefulscientificmaterialformanufacturerswhenconsideringapplicationsforbiowaiverbasedonBCSThemonographsassuchhaveno regulatoryauthority decisionswillbemadebyregulatorswhomayormaynotacceptbiowaiverdependingontheirnationallegislationandrequirements Biowaivermonographspublished StosikA G JungingerH E KoppS MidhaK K ShahV P StavchanskyS DressmanJ B BarendsD M Biowaivermonographsforimmediatereleasesolidoraldosageforms metoclopramidehydrochloride JPharmSciFeb12 2008 BeckerC DressmanJ B AmidonG L JungingerH E KoppS MidhaK K ShahV P StavchanskyS BarendsD M Biowaivermonographsforimmediatereleasesolidoraldosageforms Pyrazinamide JPharmSciFeb12 2008 BeckerC DressmanJ B AmidonG L JungingerH E KoppS MidhaK K ShahV P StavchanskyS BarendsD M Biowaivermonographsforimmediatereleasesolidoraldosageforms ethambutoldihydrochloride JPharmSciAug21 2007 BeckerC DressmanJ B AmidonG L JungingerH E KoppS MidhaK K ShahV P StavchanskyS BarendsD M Biowaivermonographsforimmediatereleasesolidoraldosageforms isoniazid JPharmSci96 2007 522 31 WHOGuidance 1 TheinvitrodissolutioninvestigationsincludingexperimentalconditionsandcharacteristicsareoutlinedinSection9oftheWHOguideline 1 Itisofutmostimportancetonotethatitisnotsufficienttodemonstratetheinvitrodissolutioncharacteristicsfortheparticularmultisourceproduct buttoensure thesimilarityofdissolutionprofilesbetweenthetestandcomparatorproducts 1 WHOguidance 2 TheWHOguidanceinbasicaspectsissimilartotheUSFDAguidanceonthebiowaiverapproach August2000 Inaddition thecurrentscientificdiscussionsintermsofsocalled biowaiverextensions arealsoconsidered Accordingly BCSbasedbiowaiversmaybeacceptablefordrugscontainingBCSclass2and3drugsubstancesmanufacturedasimmediatereleasedosageforms Asanexample abiowaivermaybepossibleforBCSclass3drugproductsthatare veryrapidly i e atleast85 dissolutionwithin15mininallrequiredmedia dissolving Therelevantdissolutioncriteriaareoutlinedinsection9 2 1oftheWHOguideline 1 Regulatorsguidanceforindustry USFDArelevanttobiowaiverguidelines www fda gov cder Guidance 3618fnl pdf Conclusions BiowaiverconceptisadevelopingconceptandnewguidancedocumentsandscientificdataareappearingPropercomparatorproductsarealsocrucialforbiowaiverRegulatoryacceptanceandpracticeofbiowaiversneedstocatchuptheconceptdevelopmentWHOwillsoonissuemorepracticalimplementationguidelinesforPQprogrammeWHOPQprogrammestartsacceptingbiowaivers asappropriate Someusefulreferences 1 Multisource generic pharmaceuticalproducts Guidelinesonregistrationrequirementstoestablishinterchangeability In WHOExpertCommitteeonSpecificationsforPharmaceuticalPreparations FortiethReport Geneva WorldHealthOrganization 2006 WHOTechnicalReportSeries No 937 Annex7 347 390 2 vanFaassenF VromansH etal Biowaiversfororalimmediate releaseproducts implicationsoflinearpharmacokinetics ClinPharmacokinet43 2004 1117 3 NotetoApplicantsontheChoiceofComparatorProductsforthePrequalificationProject LocatedontheWorldHealthOrganization WHO PrequalificationofMedicineswebsite Guidanceonselectionofcomparatorproduct Webpage http healthtech who int pq 4 Shah V P

温馨提示

  • 1. 本站所有资源如无特殊说明,都需要本地电脑安装OFFICE2007和PDF阅读器。图纸软件为CAD,CAXA,PROE,UG,SolidWorks等.压缩文件请下载最新的WinRAR软件解压。
  • 2. 本站的文档不包含任何第三方提供的附件图纸等,如果需要附件,请联系上传者。文件的所有权益归上传用户所有。
  • 3. 本站RAR压缩包中若带图纸,网页内容里面会有图纸预览,若没有图纸预览就没有图纸。
  • 4. 未经权益所有人同意不得将文件中的内容挪作商业或盈利用途。
  • 5. 人人文库网仅提供信息存储空间,仅对用户上传内容的表现方式做保护处理,对用户上传分享的文档内容本身不做任何修改或编辑,并不能对任何下载内容负责。
  • 6. 下载文件中如有侵权或不适当内容,请与我们联系,我们立即纠正。
  • 7. 本站不保证下载资源的准确性、安全性和完整性, 同时也不承担用户因使用这些下载资源对自己和他人造成任何形式的伤害或损失。

评论

0/150

提交评论